Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $75 price target after its Analyst Day presentations which “highlighted meaningful updates across the board for clinical assets as well as early- and late-stage programs currently in development.” The analyst says he continues to recommend the stock given the “number of near-term catalysts on the horizon” along with “three additional programs expected to enter the clinic in 2020.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.